Pivotal Phase II Study of Venetoclax Met Primary Endpoint

News   Aug 14, 2015

 
Pivotal Phase II Study of Venetoclax Met Primary Endpoint
 
 
 

RELATED ARTICLES

Targeting the Engine Room of the Cancer Cell

News

Researchers at Columbia University Irving Medical Center (CUIMC) have developed a highly innovative computational framework that can support personalized cancer treatment by matching individual tumors with the drugs or drug combinations that are most likely to kill them.

READ MORE

New Subtype of Prostate Cancer

News

Researchers led by the University of Michigan Rogel Cancer Center have identified a new subtype of prostate cancer that occurs in about 7 percent of patients with advanced disease.

READ MORE

Cryo-EM Reveals Interaction Between Major Drug Targets

News

For the first time, scientists have visualized the interaction between two critical components of the body's vast cellular communication network, a discovery that could lead to more effective medications with fewer side effects for conditions ranging from migraine to cancer.

READ MORE

 

Comments | 0 ADD COMMENT

Like what you just read? You can find similar content on the communities below.

Drug Discovery

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE
 

We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy